The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
An article from
Dive Brief
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
Published July 15, 2026
A Merck sign hangs on the side of an office building in South San Francisco, California.
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth…
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug…
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line…
